World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
77
Citations
26711
World Ranking
18310
National Ranking
1664

Overview

Gordon C Jayson is affiliated with the University of Manchester in the United Kingdom. Their research focuses primarily on medicine, with a substantial output in reproductive medicine, oncology, genetics, molecular biology, and surgery. Their work addresses clinical and molecular aspects within these domains, emphasizing ovarian cancer and related therapeutic approaches.

The scientist's research covers a range of main topics, including ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, BRCA gene mutations in cancer, intraperitoneal and appendiceal malignancies, CRISPR and genetic engineering, renal cell carcinoma treatment, and endometriosis research and treatment.

Jayson has contributed to several scientific publications, with frequent appearances in notable venues. These include:

  • Annals of Oncology
  • International Journal of Gynecological Cancer
  • British Journal of Cancer
  • Cancers
  • The Cambridge Structural Database

Their recent published papers demonstrate a focus on ovarian cancer and its therapeutic management. Selected recent works are:

  • "A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity," 2020, Nature Communications
  • "First-Line Management of Advanced High-Grade Serous Ovarian Cancer," 2020, Current Oncology Reports
  • "Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial," 2020, The Lancet Oncology
  • "Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial," 2021, Journal for ImmunoTherapy of Cancer
  • "Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England," 2020, European Journal of Human Genetics

Frequent collaborators in Jayson's research include Andrew R. Clamp, Robert D. Morgan, Jurjees Hasan, D. Gareth Evans, and Zena Salih. The volume of coauthored works with these colleagues ranges from 17 to 35 publications, highlighting ongoing collaborative efforts within the field.

Best Publications

  • Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

    MK Parmar;JA Ledermann;N Colombo;Bois A Du

  • Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial

    Sean Kehoe;Jane Hook;Matthew Nankivell;Gordon C Jayson

  • Imaging biomarker roadmap for cancer studies.

    James P.B. O'Connor;Eric O. Aboagye;Judith E. Adams;Hugo J.W.L. Aerts;Hugo J.W.L. Aerts

  • Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

    Amit M. Oza;Adrian D. Cook;Jacobus Pfisterer;Andrew Embleton

  • Antiangiogenic therapy in oncology: current status and future directions.

    Gordon C Jayson;Robert Kerbel;Lee M Ellis;Adrian L Harris

  • Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI.

    Geoffrey James Parker;Caleb Roberts;Andrew Macdonald;Giovanni A Buonaccorsi

  • Phase III Randomized Trial of Docetaxel–Carboplatin Versus Paclitaxel–Carboplatin as First-line Chemotherapy for Ovarian Carcinoma

    Paul Vasey;Gordon C Jayson;Alan Gordon;Hani Gabra

  • Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial.

    Gordon J.S. Rustin;Maria E.L. Van Der Burg;Clare L. Griffin;David Guthrie

  • DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents

    James P B O'Connor;Alan Jackson;Geoff J M Parker;Gordon C Jayson

  • The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations

    Martin O Leach;K Brindle;J Evelhoch;John R Griffiths

  • Intra-tumoural microvessel density in human solid tumours.

    Jurjees Hasan;Richard J Byers;Gordon C Jayson

  • Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies

    James P. B. O'Connor;Alan Jackson;Geoff J. M. Parker;Caleb Roberts

  • Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging.

    Alan Jackson;James P.B. O'Connor;Geoff J.M. Parker;Gordon C. Jayson

  • Molecular Imaging and Biological Evaluation of HuMV833 Anti-VEGF Antibody: Implications for Trial Design of Antiangiogenic Antibodies

    Gordon C Jayson;Jamal Zweit;Alan Jackson;Clive Mulatero

  • Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue.

    A.M. Wardley;G.C. Jayson;R. Swindell;G.R. Morgenstern

  • Biomarkers of angiogenesis and their role in the development of VEGF inhibitors

    N Murukesh;Caroline Dive;Gordon C Jayson

  • Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial

    Jonathan A Ledermann;Andrew C Embleton;Fharat Raja;Timothy J Perren

  • Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.

    I Vergote;C Coens;M Nankivell;G B Kristensen

  • Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer

    Jonathan A Ledermann;Allan Hackshaw;Stan B Kaye;Gordon C Jayson

  • Blockade of Platelet-Derived Growth Factor Receptor-Beta by CDP860, a Humanized, PEGylated di-Fab', Leads to Fluid Accumulation and Is Associated With Increased Tumor Vascularized Volume

    Gordon C Jayson;Geoff J M Parker;Saifee A Mullamitha;Juan W Valle

Frequent Co-Authors

Alan Jackson
Alan Jackson Arizona State University
Geoff J.M. Parker
Geoff J.M. Parker University College London
Caroline Dive
Caroline Dive University of Manchester
Jonathan A. Ledermann
Jonathan A. Ledermann University College London
Juan W. Valle
Juan W. Valle University of Manchester
Chris Todd
Chris Todd University of Manchester
John T. Gallagher
John T. Gallagher University of Manchester
Henry C Kitchener
Henry C Kitchener University of Manchester
Stan B. Kaye
Stan B. Kaye Royal Marsden NHS Foundation Trust
Fiona H Blackhall
Fiona H Blackhall University of Manchester

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in Medicine, there are numerous online degree options offering flexible pathways into healthcare careers. The demand for qualified nurses and advanced practitioners continues to rise, encouraging many to explore affordable programs designed for working adults.

If you’re considering becoming a nurse practitioner, several cheapest np school options offer accredited, high-quality education without a heavy financial burden. For those starting their nursing journey, it’s worth exploring the cheapest bsn programs online for a cost-effective entry into the field.

Advancing your nursing practice with a doctorate is also more accessible with the cheapest dnp programs online, helping you reach leadership or specialist roles. If you already hold an RN and want to advance your qualifications, check out the most affordable accredited online rn to bsn programs.

These options empower future healthcare professionals to grow their careers, increase earning potential, and contribute meaningfully to the health sector, all while managing tuition costs.

Best Scientists Citing Gordon C Jayson

Trending Scientists

Recently Published Articles